Novoprotein Scientific

Novoprotein Scientific FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Novoprotein Scientific (688137.SS) as of Oct 19, 2026 is 118.60 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 58.01 % — a change of 104.44% (higher).

FCF Conversion

118.60 %

YoY

104.44%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Novoprotein Scientific is 2025 118.60 % . FCF Conversion Rate (FCF/EBITDA) of Novoprotein Scientific was 2024 58.01 % . It decreases by 104.44% higher compared to the previous year.

The Novoprotein Scientific FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
103.27 CNY
Jan 1, 2021
0.68 CNY
Jan 1, 2022
-36.81 CNY
Jan 1, 2023
188.58 CNY
Jan 1, 2024
58.01 CNY
Jan 1, 2025
118.60 CNY
The Novoprotein Scientific FCF Conversion history
YEARFCF ConversionYoY
118.60 %+104.44%
58.01 %-69.24%
188.58 %-612.37%
-36.81 %-5,499.61%
0.68 %-99.34%
103.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Novoprotein Scientific Stock analysis

What does Novoprotein Scientific do? Novoprotein Scientific Inc, based in Suzhou, China, operates in the Health Care sector within Biotechnology. The company develops and sells recombinant protein solutions, including target and factor proteins, recombinant antibodies, enzymes, and reagents. Its products, such as novel coronavirus diagnostic antibodies and mRNA vaccine-related materials, serve biological medicine, life science research, in vitro diagnostics, and vaccine development. Employing 665 staff, Novoprotein serves domestic and international markets from its Suzhou headquarters. Novoprotein Scientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novoprotein Scientific stock

FCF Conversion Rate (FCF/EBITDA) of Novoprotein Scientific is 118.60 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Novoprotein Scientific changed from 58.01 % to 118.60 %, representing a 104.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Novoprotein Scientific since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Novoprotein Scientific with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Novoprotein Scientific

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Novoprotein Scientific